Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe and North America: 756 cases from 32 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Click a bar to drill down one level.
Where?
by regionAll jurisdictions
What for?
by action- Fine €24.6m 100 % · 2 cases
Who?
by companyWhen?
per quarter, by date of decision| Period | Cases | Total |
|---|---|---|
| Q3 2023 | 0 | — |
| Q4 2023 | 1 | €13.4m |
| Q1 2024 | 0 | — |
| Q2 2024 | 0 | — |
| Q3 2024 | 0 | — |
| Q4 2024 | 0 | — |
| Q1 2025 | 0 | — |
| Q2 2025 | 1 | €11.2m |
| Q3 2025 | 0 | — |
| Q4 2025 | 0 | — |
| Q1 2026 | 0 | — |
| Q2 2026 | 0 | — |
| Q3 2026 | 0 | — |
2 cases
24 Apr 2025 Johnson & Johnson Consumer NV; Boehringer Ingelheim SComm; Haleon Belgium NVJohnson & Johnson, Boehringer, Haleon: 11.2 million EUR for shelf-placement collusion in pharmacies €11.2m
Over more than 15 years, the three OTC medicine manufacturers jointly developed the category management project ‘SMAN’, through which they steered the placement of non-prescription medicines in selected pharmacies in their favour and disadvantaged or excluded competing products. In a settlement procedure, the Autorité belge de la Concurrence / Belgische Mededingingsautoriteit (Belgian Competition Authority, BMA) imposed a total of 11,249,280.48 EUR.
Category management agreements with retailers must not push competitors off the shelf – joint planograms with competitors are off limits.
Competition law limits of category management
- Authority / court
- Autorité belge de la Concurrence / Belgische Mededingingsautoriteit (BMA)
- Area of law
- Competition law · Cartels and collusion
- Legal basis
- Code de droit économique Art. IV.1; AEUV Art. 101
- Action
- Fine
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
- Employees
- 10,000 or more
- Published
- 24 Apr 2025
- BMA – Communiqué de presse N°16/2025 (24.04.2025) Press release of an authority
- BMA – Beslissing BMA-2025-RPR-13-AUD (SMAN), publieke versie Decision of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
19 Oct 2023 Alkaloids of Australia, Alkaloids Corporation, Boehringer, Linnea, Transo-Pharm (C2 PHARMA Kronzeuge)EU: 13.4 million EUR against pharmaceutical ingredient cartel (SNBB for Buscopan) €13.4m
From 2005 to 2019, six manufacturers and traders of the active ingredient SNBB (the base substance for Buscopan and generics) fixed minimum prices, allocated quotas and exchanged sensitive information. This was the first cartel concerning an active pharmaceutical ingredient that the Commission has sanctioned; C2 PHARMA received full immunity, and all parties reached a settlement.
Even small niche markets for active ingredients are in the spotlight – contacts with competitors about prices or volumes are off-limits.
Price and quota agreements in the trade in active ingredients
- Authority / court
- Europäische Kommission
- Area of law
- Competition law · Cartels and collusion
- Legal basis
- Art. 101 AEUV, Art. 53 EWR-Abkommen
- Action
- Fine
- Status of proceedings
- unknown
- Sector
- Chemicals and pharmaceuticals
- Mitigating circumstances
- Leniency programme (C2 PHARMA 100 %, Transo-Pharm 50 %, Linnea 30 %), 10 % settlement reduction
- Commission fines pharma companies €13,4 million in antitrust cartel settlement (IP/23/5104) Press release of an authority
Checked against the official source on 25 Sep 2026 · Direct link